Swedish Orphan Biovitrum AB (publ) (SOBI) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Swedish Orphan Biovitrum AB (publ) stock SEK 531, price SEK 494, upside +7.5%, quality 63 out of 100. Rating: fairly valued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range kr 163.10 – kr 493.60 · fair‑value band kr 330.55 – kr 758.11 · the kr 493.60 price screens below the kr 530.86 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Swedish Orphan Biovitrum AB (publ) in your weekly email
Every Wednesday you see whether Swedish Orphan Biovitrum AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care.
Show moreShow less
It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.
The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer.
The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Stock analysis
Swedish Orphan Biovitrum AB (publ) (SOBI) currently trades at kr 493.60, while our model-based Fair Value estimate is kr 530.86, so the stock looks roughly fairly valued today (gap 7.0%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 541.32 per share, and 7 of the 22 models we run sit above the kr 493.60 price.
Bear case: the Economic Profit group reads lowest at kr 73.14, and 15 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: kr 330.55 (bear) to kr 758.11 (bull), the price of kr 493.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Swedish Orphan Biovitrum AB (publ) reported revenue of 28.2B SEK in FY2025 versus 15.5B SEK in FY2021, a compound +16.1%/yr. Reported net income was 478M SEK in FY2025, compounding −35.0%/yr from FY2021.
Key figures
Market cap 173B SEK (≈ $17.6B) Large · P/E ratio 26.1 · P/S ratio 5.41 · EPS (TTM) kr 18.94 · Net margin 20.7% · Return on equity 16.3% · Return on assets (EBIT) 8.0% · Operating margin 36.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 68 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 56% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 8%, SOBI screens cheaper than that median.
Fair Value models
Bearkr 330.55Fair Value kr 530.86Bullkr 758.11
Price kr 493.60 · Upside +7.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 16.09 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.98/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
Start year 2020 (pandemic). Over 10 years: +24.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−33.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−33.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−33.3% vs −1.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.32% → 29%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +3.6% a year for the price and +10.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Pipeline expansion via the Innate Pharma partnership broadens the business beyond rare diseases, yet limited evidence of durable advantages and weak reported returns constrain overall quality.
Main risk: The US patent for Doptelet expires in July 2027 which could allow generic competition and pressure sales of this key product.
Bull case: Sobi could offset patent losses and competition through successful launches of new assets like lacutamab and Tryngolza plus international expansion to sustain growth toward its 2030 ambition.
Bear case: If patent expiries and rivals materialise without sufficient new revenue from the pipeline Sobi could face prolonged revenue stagnation or decline in its core hematology and immunology segments.
Sobi has made its partnership with Innate Pharma for lacutamab in T-cell lymphoma effective, broadening the pipeline beyond core rare diseases. This arrives alongside an expected Q3 earnings decline and a CEO transition set for early 2027. Will the new asset drive enough fresh growth to balance the leadership shift and near-term softness?
Compare Swedish Orphan Biovitrum AB (publ) with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 554 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Above median
Fair Value upside+7.5% · Above median
Profitability
Return on equity (12 months)16.3% · Top 25%
Return on assets0.7% · Below median
Net margin (12 months)20.7% · Top 25%
Operating margin (12 months)36.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)17.3% · Above median
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)26.1× · Pricier than median
P/B4.58× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Swedish Orphan Biovitrum AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/SOBI
Frequently asked questions
Is Swedish Orphan Biovitrum AB (publ) (SOBI) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of kr 530.86 versus a price of kr 493.60, about +8% upside (fairly valued).
What is the fair value of SOBI?
Our model-based fair value for Swedish Orphan Biovitrum AB (publ) is kr 530.86 (as of Nov 5, 2026), built from audited fundamentals. The current price: kr 493.60.
What is the quality score of SOBI?
Swedish Orphan Biovitrum AB (publ) has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Swedish Orphan Biovitrum AB (publ) (SOBI)?
Our model-based price target is the fair value of kr 530.86 (as of Nov 5, 2026) from 22 valuation models. Cautious scenario kr 330.55, optimistic scenario kr 758.11. It is a calculation from audited fundamentals, not an analyst target.
What is the Swedish Orphan Biovitrum AB (publ) stock forecast for 2026?
Our models put fair value at kr 530.86, about +8% upside versus a price of kr 493.60 (fairly valued). Cautious scenario kr 330.55, optimistic scenario kr 758.11. The calculation is refreshed regularly with new filings.
What is the revenue of Swedish Orphan Biovitrum AB (publ) (SOBI)?
Swedish Orphan Biovitrum AB (publ) reported trailing-twelve-month revenue of about 32.0B SEK (latest available figure, as of Nov 5, 2026).
What growth is priced into Swedish Orphan Biovitrum AB (publ) (SOBI)?
For today's price to be fair in a discounted-cash-flow model, Swedish Orphan Biovitrum AB (publ) would have to grow free cash flow by +5.7 % per year for five years (discount rate 7.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.1 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of SOBI use?
Our models discount Swedish Orphan Biovitrum AB (publ) at 7.9 %: a base by market capitalisation (large), damped by beta 0.36, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Swedish Orphan Biovitrum AB (publ) that is +5.7 % per year a year over ten years, using the same discount rate (7.9 %) and the same formula as our fair value.
How much growth has Swedish Orphan Biovitrum AB (publ) (SOBI) delivered so far?
Over the past 5 years revenue at Swedish Orphan Biovitrum AB (publ) grew +13.1 % a year. The price currently implies +5.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Swedish Orphan Biovitrum AB (publ) (SOBI) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Swedish Orphan Biovitrum AB (publ) (+5.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Swedish Orphan Biovitrum AB (publ) (SOBI)?
The free-cash-flow yield on the price is 4.93 %: that much free cash flow Swedish Orphan Biovitrum AB (publ) produces per unit of market value. When it exceeds the discount rate of our models (7.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Swedish Orphan Biovitrum AB (publ) (SOBI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Swedish Orphan Biovitrum AB (publ) it is kr 530.86 per share (as of Nov 5, 2026), against a price of kr 493.60. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Swedish Orphan Biovitrum AB (publ) stock overvalued or undervalued in 2026?
As of Nov 5, 2026, SOBI trades below its calculated fair value: price kr 493.60, fair value kr 530.86, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOBI?
No. The price is what the market pays today (kr 493.60); the fair value is what the company's own numbers justify (kr 530.86). For Swedish Orphan Biovitrum AB (publ) the two are kr 37.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Swedish Orphan Biovitrum AB (publ) worth?
The market values Swedish Orphan Biovitrum AB (publ) at about 173B SEK (market capitalisation, as of Nov 5, 2026). Per share that is kr 493.60; our models calculate a fair value of kr 530.86 per share.
What do the bullish and bearish scenarios say about SOBI?
Our models span a range for Swedish Orphan Biovitrum AB (publ): cautious scenario kr 330.55, base kr 530.86, optimistic kr 758.11 per share (as of Nov 5, 2026, price kr 493.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SOBI?
Swedish Orphan Biovitrum AB (publ) trades at a price-to-earnings ratio of 26.1 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 530.86 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 29.4 (reported for FY2025: 360.0). Other multiples: PEG 0.3, P/B 4.6, P/S 5.4, EV/EBITDA 13.8.
What is the PEG ratio of SOBI?
The PEG ratio of Swedish Orphan Biovitrum AB (publ) is 0.26 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Swedish Orphan Biovitrum AB (publ) (SOBI)?
Balance-sheet figures for Swedish Orphan Biovitrum AB (publ) (as of Nov 5, 2026): return on equity 16.3%, debt of 0.14 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is SOBI from its 52-week high?
Swedish Orphan Biovitrum AB (publ) trades at kr 493.60, at its 52-week high of kr 493.60 and 56% above the low of kr 317.00 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of kr 530.86 is for.
Which stocks are comparable to Swedish Orphan Biovitrum AB (publ)?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Swedish Orphan Biovitrum AB (publ) stock attractive at the current price?
The data as of Nov 5, 2026: price kr 493.60, calculated fair value kr 530.86 (+8%), Quality Score 63/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SOBI calculated?
We run Swedish Orphan Biovitrum AB (publ) through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 530.86, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Swedish Orphan Biovitrum AB (publ) currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Swedish Orphan Biovitrum AB (publ) (SOBI)?
The closing price on Nov 5, 2026 was kr 493.60. Our model-based fair value is kr 530.86, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Swedish Orphan Biovitrum AB (publ) right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (kr 330.55 to kr 758.11) leaves room in how you read the outcome.
Where does the earnings growth of Swedish Orphan Biovitrum AB (publ) (SOBI) come from?
Earnings per share at Swedish Orphan Biovitrum AB (publ) grew +17.9 % a year from 2015 to 2025. Broken into its drivers: revenue per share +20.2 %, EBIT margin +5.1 %, tax rate +2.0 %, residual (interest, one-offs) −8.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Swedish Orphan Biovitrum AB (publ)
How large is the market capitalisation of Swedish Orphan Biovitrum AB (publ) (SOBI)?
The market capitalisation of Swedish Orphan Biovitrum AB (publ) is 173B SEK (≈ $17.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Swedish Orphan Biovitrum AB (publ) (SOBI)?
The price-to-sales ratio of Swedish Orphan Biovitrum AB (publ) is 5.41 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Swedish Orphan Biovitrum AB (publ) (SOBI)?
Earnings per share at Swedish Orphan Biovitrum AB (publ) are kr 18.94 (price ÷ EPS = P/E 26.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Swedish Orphan Biovitrum AB (publ) (SOBI)?
The net margin of Swedish Orphan Biovitrum AB (publ) is 20.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Swedish Orphan Biovitrum AB (publ) (SOBI)?
The return on equity (ROE) of Swedish Orphan Biovitrum AB (publ) is 16.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Swedish Orphan Biovitrum AB (publ) (SOBI)?
On an EBIT basis the return on assets of Swedish Orphan Biovitrum AB (publ) is 8.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Swedish Orphan Biovitrum AB (publ) (SOBI)?
The operating margin of Swedish Orphan Biovitrum AB (publ) is 36.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Swedish Orphan Biovitrum AB (publ) (SOBI)?
Revenue at Swedish Orphan Biovitrum AB (publ) is growing +17.3% versus a year earlier (3y avg +14.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Swedish Orphan Biovitrum AB (publ) (SOBI)?
Earnings per share at Swedish Orphan Biovitrum AB (publ) are growing +71.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Swedish Orphan Biovitrum AB (publ) (SOBI) carry?
The net debt of Swedish Orphan Biovitrum AB (publ) is 10.7B SEK (fiscal year 2025, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Swedish Orphan Biovitrum AB (publ) in the live analysis
One click puts Swedish Orphan Biovitrum AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026